Trials
Search / Trial NCT05649280

Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients

Launched by SOUTIEN AUX ACTIONS CONTRE LES MALADIES DU GLOBULE ROUGE · Dec 12, 2022

Trial Information

Current as of February 05, 2025

Completed

Keywords

ClinConnect Summary

This prospective, observational study will take place, as follows:

Calculation of the PRESEV score in the ER will determine or not eligibility of the patient in the DREPADOM structure. With a low score, a patient is eligible for home monitoring and after duly provided information, can sign a patient consent for the use of personal medical data.

The coordinating nurse from DREPADOM can then set up a whole network, with the delivery of oxygen supply at the patient's house, dispatch of a medical prescription to a neighboring pharmacy and daily visits from homecare service providers. Both opi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • SS or Sβ0
  • Adult patients with a low PRESEV score
  • Exclusion Criteria:
  • SC/Sβ+ patients
  • SCD adult patients with an intermediate or high PRESEV score
  • Pregnant or breastfeeding women
  • Homeless patient
  • Patients without Social Security
  • Patient deprived of liberty by judicial or administrative decision or patient under guardianship

Trial Officials

Pablo BARTOLUCCI, PROFESSOR

Principal Investigator

Soutien aux Actions contre les Maladies du Globule Rouge

About Soutien Aux Actions Contre Les Maladies Du Globule Rouge

Soutien aux Actions Contre les Maladies du Globule Rouge (SAMG) is a dedicated clinical trial sponsor focused on advancing research and treatment options for red blood cell disorders. Committed to improving patient outcomes, SAMG collaborates with leading healthcare professionals, academic institutions, and industry partners to design and implement innovative studies that address the complexities of these diseases. By prioritizing rigorous scientific methodology and ethical standards, SAMG aims to enhance understanding, develop new therapies, and ultimately contribute to the well-being of individuals affected by red blood cell conditions.

Locations

Creteil, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials